Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of 600 mg daily oral dose of rifampin (CYP3A4 inducer) on
the pharmacokinetics of a single 400 mg oral dose of nilotinib in healthy subjects